Robert M. Crawford, Jr.

Robert M. Crawford, Jr.

Partner
Robert M. Crawford, Jr.

Robert Crawford is a partner in the firm’s Technology Companies + Life Sciences Group and is a leader in the firm’s generic pharmaceutical transactions practice. Mr. Crawford represents technology, pharmaceutical and other life science companies in connection with their commercial, M&A and intellectual property transactions, including complex strategic collaboration, co-development, licensing and partnering transactions. He also has extensive experience structuring and negotiating brand and generic settlement and license agreements related to ANDA litigation and other Hatch-Waxman patent disputes.

Experience

Mr. Crawford’s representative transactions include:

  • Teva Pharmaceuticals, in its $40.5 billion acquisition of Allergan’s (fka Actavis/Watson) Global Generic Pharmaceuticals Business.
  • Teva Pharmaceuticals, in its $410 million exclusive collaboration and license agreement with Heptares Therapeutics Limited regarding its preclinical small-molecule calcitonin gene-related peptide (CGRP) antagonist program.
  • Teva Pharmaceuticals, in connection with its sale of oncology assets to Ignyta.
  • Cephalon, in its exclusive license agreement with Eagle Pharmaceuticals related to BendekaTM with a total deal value in excess of $120 million, plus royalties.
  • Cipla, in connection with its $550 million acquisition of InvaGen Pharmaceuticals Inc. and Exelan Pharmaceuticals Inc.
  • Lupin, in connection with exclusive collaboration and license agreement regarding development and commercialization of innovative drug products and new platform technologies.
  • Syqe Medical, in connection with $20 million investment by Philip Morris and related exclusive license and development agreement regarding innovative inhaler products.
  • Pharmascience, in connection with its strategic partnership with Bion Pharmaceuticals.
  • Teva Pharmaceuticals, in connection with patent license and settlement agreements related to settlements of various brand and generic pharmaceutical patent litigation matters.
  • Fresenius Kabi, in connection with patent license and settlement agreements related to settlements of various pharmaceutical patent litigation matters.
  • Lupin, in connection with patent license and settlement agreements related to settlements of various pharmaceutical patent litigation matters.
  • West-Ward Pharmaceuticals, in connection with patent license and settlement agreements related to settlements of various pharmaceutical patent litigation matters.
  • Glenmark, in connection with patent license and settlement agreements related to settlements of various pharmaceutical patent litigation matters.
  • Alere, Inc., with respect to a 50/50 joint venture with The Procter & Gamble Company for existing and to-be-developed consumer diagnostic products.
  • Alere, Inc., with respect to its acquisition of ACON Laboratories Inc.'s worldwide lateral flow immunoassay business and its manufacturing facility in Hangzhou, China.
  • Alere, Inc., with respect to its acquisition of Biosite, Inc., a leading provider of rapid diagnostic products.
  • Citrix Systems, Inc., in its $1.8 billion spin-out of its GoTo family of products.
  • Citrix Systems, Inc., with respect to a strategic alliance with Cisco regarding solutions to help customers simplify and accelerate large-scale desktop virtualization deployments, including the deployment HD virtual desktops and applications over a Citrix HDX™-enabled Cisco® network.
  • Citrix Systems, Inc., with respect to a collaboration agreement with Microsoft regarding rich graphics support for virtual desktops through the Microsoft RemoteFX technology platform. 
  • Citrix Systems, Inc., with respect to a collaboration agreement with Intel regarding a bare-metal Xen-based desktop hypervisor optimized for Intel® virtualization technology.
  • Digital Sky Technologies Limited, with respect to its $187.5 million purchase of the ICQ instant messaging business from AOL Inc.
  • Zebra Technologies, in a spin-out of its terminal operator systems business to Cargotec Corp.
  • Thoma Bravo, LLC, in its acquisition of Roadnet Technologies Inc. (transportation and logistics solutions division formerly known as UPS Logistics Technologies) from United Parcel Service, Inc.
Professional Activities

Mr. Crawford is a member of the Boston Bar Association, Boston College Law School Intellectual Property Inn of Court and the American Bar Association. He also provides extensive pro bono services to a variety of clients as a member of the Volunteer Lawyers for the Arts in Boston and Volunteer Lawyers Project of the Boston Bar Association. In addition, he has served as a mentor to Boston area middle school students as part of the Legal Apprenticeship Program, in partnership with Citizen Schools and Discovering Justice.

Professional Experience

Prior to joining Goodwin, Mr. Crawford spent six years working for The Gillette Company as a project manager focusing on business process integration, supply chain management, data warehousing, customer relationship management and electronic commerce.

Recognition

Mr. Crawford has been recognized as a Massachusetts Super Lawyer “Rising Star” by Law & Politics and Boston magazine.

Credentials

Education

J.D., 2000
Suffolk University School of Law

(cum laude, high technology law concentration with distinction)

B.S., 1995
Boston University

Admissions

Bar

Massachusetts
New York

Courts

U.S. Court of Appeals for the First Circuit
U.S. District Court for the District of Massachusetts
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Search Other Lawyers